Tomasz Beer

Tomasz Beer is a prostate cancer specialist at OHSU who has contributed to advancing the evidence base for nmCRPC through leadership in the SPARTAN trial and other phase III investigations. His research has helped validate metastasis-free survival as a regulatory endpoint and demonstrated overall survival benefits with AR pathway inhibitors in nmCRPC. He leads translational research programs examining mechanisms of hormonal resistance and novel combination strategies. Beer has been central to regulatory approvals of multiple prostate cancer agents.